Ionis Pharmaceuticals Inc at JPMorgan NAPA Valley Forum (Virtual) Transcript
Great. Thanks, everyone, for joining us. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing our virtual Napa Valley Biotech Forum with Ionis today. I'm joined by the company's CEO (sic) [CFO], Beth Hougen.
Questions & Answers
So maybe we can get right into it. Since Brett became CEO last year, the company has evolved its strategy and is now planning to commercialize some of its wholly owned medicines independently. So what's Ionis' strategy on which drugs it's going to commercialize? And do you still plan to partner some programs? And how will you decide?
Great. Thanks, Jess, and thank you for having us. We're happy to be here this afternoon. It's a great question, and we're so excited about the future of the company right now with such a deep
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |